title: Medical treatment of gastroesophageal reflux disease does not prevent the development of Barrett's metaplasia and poor esophageal body motility.
abstract: OBJECTIVE
  Duodenal contents refluxing into the esophagus may be involved in the pathophysiology of gastroesophageal reflux disease (GERD). This study was performed to investigate whether medical treatment of GERD aimed at suppression of gastric acid production can prevent the development of complications, such as Barrett's metaplasia or poor esophageal body motility.
  
  
  METHODS
  Retrospective study.
  
  
  METHODS
  University hospital.
  
  
  METHODS
  138 GERD patients were analyzed regarding the development of Barrett's metaplasia or poor esophageal body motility, despite intermittent or continuous treatment with H2 blockers or omeprazole.
  
  
  METHODS
  The rate of patients with Barrett's metaplasia or poor esophageal body motility with or without effective medical treatment.
  
  
  RESULTS
  Barrett's metaplasia was found in 33.8% of patients receiving medical treatment, although it was not present when treatment was induced. This rate was 21.9% among patients who were not receiving therapy (not significant). In all, 41.9% of patients with medication had impaired esophageal body motility compared with 59.3% of patients not receiving treatment (P < 0.05), but these patients had a significantly shorter history of GERD.
  
  
  CONCLUSIONS
  Medical treatment with H2 blockers or omeprazole does not prevent the development of Barrett's metaplasia or poor esophageal body motility.
authors.affiliation: 2nd Department of Surgery, University of Innsbruck, Austria.
authors.forename: G J
authors.initials: GJ
authors.lastname: Wetscher
authors.forename: C
authors.initials: C
authors.lastname: Profanter
authors.forename: M
authors.initials: M
authors.lastname: Gadenstätter
authors.forename: G
authors.initials: G
authors.lastname: Perdikis
authors.forename: K
authors.initials: K
authors.lastname: Glaser
authors.forename: R A
authors.initials: RA
authors.lastname: Hinder
mesh_terms: D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001471:Barrett Esophagus / Q000473:pathology / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D015154:Esophageal Motility Disorders / Q000473:pathology / Q000517:prevention & control*; D004945:Esophagoscopy; D004947:Esophagus / Q000187:drug effects / Q000473:pathology; D005500:Follow-Up Studies; D005745:Gastric Acidity Determination; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000473:pathology; D006635:Histamine H2 Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008365:Manometry; D009853:Omeprazole / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D009853:Omeprazole